Biomarkers in GIST: Partly ready for prime-time use

Clinical Cancer Research

Volumn 15, Issue 18, 2009, Pages 5603-5605

  Blanke, Charles D ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE F 18; IMATINIB; PROTEIN TYROSINE KINASE; SUNITINIB;

BIOLOGICAL THERAPY; CANCER CELL; CELL DEATH; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; GASTROINTESTINAL STROMAL TUMOR; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICIAN; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; REVIEW; TREATMENT FAILURE; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; GASTROINTESTINAL STROMAL TUMORS; HUMANS; INDOLES; PREDICTIVE VALUE OF TESTS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT; PYRROLES; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 70349463111     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-1563     Document Type: Review

References (6)

1. Demetri GD, Heinrich MC, Fletcher JA, et al. Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. Clin Cancer Res 2009;15:5902-5909
2. DePrimo SE, Huang X, Blackstein ME, et al. Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure. Clin Cancer Res 2009;15:5869-5877
3. Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008;26:620-625 (Pubitemid 351264357)
4. Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria. J Clin Oncol 2007;25:1753-1759 (Pubitemid 46797957)
5. Bono P, Krause A, von Mehren M, et al. Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib. Blood 2004;103:2929-2935 (Pubitemid 38451662)
6. DePrimo SE, Wong LM, Nicholas SL, et al. Decreases in circulating levels of soluble KIT in patients with imatinib-resistant gastrointestinal stromal tumor receiving the novel kinase inhibitor SU11248: Correlative analysis of blood and plasma biomarkers. Proc Am Assoc Cancer Res 2003;44:678-679